The economic effects of the possible introduction of follow-on protein products have been the subject of recent debate. In a study by Mr Michael Lanthier, Ms Rachel Behrman and Mr Clark Nardinelli of the US FDA, it was aimed to explore the economic issues surrounding this debate using three measures: total sales, product complexity and patent expiry.
Economic issues with follow-on protein products
Biosimilars/Research | Posted 30/07/2009 0 Post your comment
Their analysis shows that the sales of therapeutic protein products are concentrated in a relatively small number of branded products, which may be the most attractive targets for follow-on development. Many of these products are complex proteins that are reported to have patent coverage for several more years.
However, if reported patent expiration estimates hold, in the not-too-distant future, a significant number of important protein products with large current sales will lose patent protection. For the years 2013–2015, they estimate that products representing US$20 billion (Euros 14.3 billion) in annual sales – approximately half of all sales in 2006 – can be expected to lose patent protection.
The majority of the products were licensed under the Public Health Service Act, which lacks an abbreviated pathway for approval of follow-on products, creating uncertainty for potential developers of follow-on products.
Source: Nature Reviews 7;2008:733.
News
First denosumab biosimilars approved in Canada and the US
Dr Reddy's launches bevacizumab biosimilar Versavo in the UK
General
Brazil advances in follow-on biologicals/biosimilars approvals, trailing Europe
Insurer perspective on increasing biosimilar uptake in Canada
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Comparing biosimilar adoption: Medicare Advantage versus traditional Medicare
Questioning the need for ethnic sensitivity assessments for biosimilar monoclonal antibodies
ANVISA's role in biosimilar medicine regulation and innovation promotion
Infliximab discontinuation in patients with originator retransition vs biosimilar continuation
Comments (0)
Post your comment